Good evening :)
Place Order
Add to Watchlist

Solara Active Pharma Sciences Ltd

SOLARA

Solara Active Pharma Sciences Ltd

SOLARA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,773 cr, stock is ranked 885
High RiskStock is 3.88x as volatile as Nifty
682.853.42% (+22.60)
682.853.42% (+22.60)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,773 cr, stock is ranked 885
High RiskStock is 3.88x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,773 cr, stock is ranked 885
High RiskStock is 3.88x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-7.044.03
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.496.670.52%

Forecast & Ratings

Detailed Forecast 
0%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

SSL Pharma Sciences is a manufacturer of pharmaceutical preparation

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -1.54%, vs industry avg of 9.04%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.64% to 0.34%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue523.431,399.061,349.271,645.651,288.361,466.361,294.291,261.63
Raw Materialssubtract274.29738.62653.03726.57912.64781.78765.751,492.25
Power & Fuel Costsubtract31.4179.3577.6885.4293.70108.10122.56
Employee Costsubtract68.53185.81204.13229.37236.34228.63243.92
Selling & Administrative Expensessubtract22.6664.4869.2373.7774.6066.9370.53
Operating & Other expensessubtract67.23105.2958.24115.88-125.42124.49371.51
Depreciation/Amortizationsubtract33.9883.1094.16108.66112.32111.19103.33101.62
Interest & Other Itemssubtract25.1482.4277.8984.4875.2890.06105.11115.21
Taxes & Other Itemssubtract-0.180.480.300.10-32.95-22.6478.9788.68
EPS0.1421.7440.1465.00-14.90-5.68-145.27-137.27
DPS0.004.611.846.450.002.760.000.00
Payout ratio0.000.210.050.100.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF

Investor Presentation

May 14PDF
May 4PDF
Oct 14PDF
FY 2021

Annual report

PDF

Investor Presentation

Apr 11PDF
FY 2022

Annual report

PDF

Investor Presentation

May 2PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Solara Active Pharma Sciences Ltd-6.654.03
Sun Pharmaceutical Industries Ltd46.136.580.73%
Cipla Ltd29.214.490.87%
Mankind Pharma Ltd62.9112.57

Price Comparison

Compare SOLARA with any stock or ETF
Compare SOLARA with any stock or ETF
SOLARA
Loading...

Shareholdings

Promoter Holdings Trend

Increased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 6.78%

High Pledged Promoter Holding

Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.51%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding37.27%1.28%2.10%14.25%45.11%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep18.71%17.86%16.62%15.80%14.00%14.25%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 4 Mutual Funds holding Solara Active Pharma Sciences Ltd




Funds (Top 4)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct Plan

Growth
0.9755%0.16%0.03%80/89 (-7)
Aditya Birla Sun Life Midcap Fund - Growth - Direct Plan

Growth
0.3019%0.19%0.04%77/97 (-5)
Aditya Birla Sun Life Manufacturing Equity Fund - Growth - Direct Plan

Growth
0.1510%0.46%0.08%32/73 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 18, 2021

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Aug 18, 2021

Cash Dividend

Ex DateEx DateNov 19, 2020

Interim
Interim | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Nov 19, 2020

Cash Dividend

Ex DateEx DateJul 28, 2020

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jul 28, 2020

Cash Dividend

Ex DateEx DateAug 6, 2019

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Aug 6, 2019

News & Opinions
Earnings
Solara Active Pharma Sciences reports consolidated net profit of Rs 8.01 crore in the September 2024 quarter

Net profit of Solara Active Pharma Sciences reported to Rs 8.01 crore in the quarter ended September 2024 as against net loss of Rs 17.16 crore during the previous quarter ended September 2023. Sales declined 18.41% to Rs 346.95 crore in the quarter ended September 2024 as against Rs 425.24 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales346.95425.24 -18 OPM %17.678.85 - PBDT33.3514.37 132 PBT8.01-11.84 LP NP8.01-17.16 LP Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences allots 49,000 equity shares under ESOP

Solara Active Pharma Sciences has allotted 49,000 equity shares under ESOP on 21 October 2024. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences to declare Quarterly Result

Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 21 October 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences schedules AGM

Solara Active Pharma Sciences announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Solara Active Pharma Sciences reports consolidated net loss of Rs 13.46 crore in the June 2024 quarter

5 months agoBusiness Standard
Corporate
Solara Active Pharma Sciences to conduct board meeting

Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 22 July 2024.Powered by Capital Market - Live

5 months agoCapital Market - Live

Solara Active Pharma Sciences closes its rights issue for raising Rs 449.95 cr

6 months agoBusiness Standard

Solara Active Pharma Sciences gain on USFDA all-clear for Cuddalore unit

1 year agoMoneycontrol

Solara Active Pharma Science gains on board nod to raising up to Rs 450 crore

1 year agoMoneycontrol

Solara Active Pharma spurts 9% on heavy volumes

1 year agoMoneycontrol